You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

shingrix_logo

Product menu

shingrix-in-your-practice-banner
Incorporating SHINGRIX▼ into your practice

Protecting your patients from shingles involves proper administration, discussing disease risk and vaccination, and ensuring series completion.

Dosing and administration

SHINGRIX▼ is a recombinant vaccine indicated for prevention of herpes zoster (HZ) and HZ-related complications,
such as post-herpetic neuralgia (PHN), in adults 50 years of age or older and adults 18 years of age or older at increased risk of HZ.1
SHINGRIX▼ is not indicated for prevention of primary varicella infection.1

shingrix-in-your-practice-calender-icon

SHINGRIX▼ is given as a 2-dose series:

The primary vaccination schedule consists of two doses of 0.5 ml each; an initial dose followed by a second dose 2 to 6 months later.1

For subjects who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, and whom would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose.1

shingrix-in-your-practice-bottle-icon

SHINGRIX▼ is supplied as 2 vials for reconstitution:

The vial containing the suspension should be reconstituted with the vial containing the powder.1

shingrix-in-your-practice-tube-icon

SHINGRIX▼ should be refrigerated. DO NOT FREEZE.

Store in a refrigerator (2° C - 8° C). After reconstitution, SHINGRIX▼ is stable for 6 hours when kept in a refrigerator (2° C - 8° C).1

shingrix-in-your-practice-injection-icon

SHINGRIX▼ is only for intramuscular injection.1

 

 

Making it part of your routine

shingrix-in-your-practice-warning-icon

Explain their risk of shingles:

  • Risk increases with age, especially after 50 years old2,3
  • Shingles can be painful and lead to serious complications3,4
shingrix-in-your-practice-number-icon

Stress the protection benefit of both doses:

  • SHINGRIX▼ is a 2-dose series1
  • The second dose is given 2 to 6 months after the first dose1
  • Need both doses to ensure protection1
shingrix-in-your-practice-chat-icon

Tell them what to expect:

  • The specific side effects they are likely to encounter
  • The median duration of the majority of these events

Ensuring series completion

shingrix-in-your-practice-bigcalender-icon

Schedule the follow-up immediately:

Patients can receive the second dose in as soon as 2 months (and any time between 2-6 months).1

shingrix-in-your-practice-phone-icon

Call ahead:

Have the office staff call patients in advance of their follow-up.

shingrix-in-your-practice-hand-icon

Encourage reminder:

Once you set a date, have your patients place a reminder in their calendar.

Why Shingrix second dose?

Video player requires JavaScript enabled. You can download this video here: https://videos.gskinternet.com/pharma/GSKpro/SaudiArabia/MP4/Shingrix/second_dose_video_with_english_subtitles_saudi_arabia.mp4

Watch the video to see the value of Shingrix▼ 2nd dose on patients' quality of life.

View reconstitution instructions for SHINGRIX▼

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/SaudiArabia/MP4/Shingrix/ksa_2022_shingrix_reconstitution_video_pm_sa_sgx_vid_220001.mp4

You and your office staff can learn how to administer SHINGRIX▼ step by step.

shingrix_icons_efficacy

SHINGRIX▼ protects appropriate patients1

SHINGRIX▼ delivered >90% efficacy against shingles in all age segments ≥50 years old

Learn more

shingrix_icons_people

Meet the patients you can protect1-3, 5

Nearly everyone ≥50 years old needs shingles protection

Learn more

shingrixshingrix_in_your_practice_icons_virus

Formulated to address age-related decline in immunity1-3, 6-10

SHINGRIX▼ generates a strong and sustained immune response

Learn more

Shingrix▼ Safety Information1

Contraindications:
Hypersensitivity to the active substances or to any component of the vaccine.

Special warnings and precautions:
As with all injectable vaccines:
- appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine;
- vaccination with Shingrix▼ should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination;
- a protective immune response may not be elicited in all vaccinees.
Do not administer the vaccine intravascularly, intradermally or subcutaneously.
There are no data on the use of Shingrix▼ in pregnant women and the effect on breast-fed infants of administration of Shingrix▼ to their mothers has not been studied.

Adverse reactions:
- Very common (≥1/10): headache, gastrointestinal symptoms (including nausea, vomiting, diarrhoea and/or abdominal pain), myalgia, injection site reactions (such as pain, redness, swelling), fatigue, chills, fever.
- Common (≥1/100 to <1/10): injection site pruritus, malaise.
Please refer to the full prescribing information for further details.

References

  1. Approved prescribing information by SFDA for Shingrix▼.
  2. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356(13):1338-43.
  3. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008 May;57(RR-5):1-30.
  4. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014 Jun; 4(6):e004833.
  5. Kilgore PE, Kruszon-Moran D, Seward JF, Jumaan A, Van Loon FP, Forghani B, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-18.
  6. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012 Aug;24(4):494-500.
  7. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372(22):2087-96.
  8. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JAR, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar;32(15):1745-53.
  9. Bharucha T, Ming D, Breuer J. A critical appraisal of ‘Shingrix▼’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother. 2017 Aug;13(8):1789-97.
  10. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375(11):1019-32.

▼This medicine is subjected to additional monitoring. This will allow quick identification of new safety information. You may help by reporting any side effects you may get.

For more information, please refer to the prescribing information or contact GSK: P.O Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia.
Telephone: +966 12 653 6666 or via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com
To report the Quality related product complaint/s associated with the use of GSK product/s, please contact us via ksa.productqualitycomplaint@gsk.com

GSK does not recommend, endorse or accept liability for sites controlled by a third party.

Trademarks are owned by or licensed to the GSK group of companies.
©2025 GSK group of companies or its licensor
GlaxoSmithKline, Jeddah, 21544, Kingdom of Saudi Arabia.

PM-SA-SGX-WCNT-240011 Date of preparation: March 2025